SeekingAlpha · Jan 26, 2026
IGRO: International ETF Heavily Weighted In Financials, Downplays China
The iShares International Dividend Growth ETF offers diversified exposure to 557 international stocks. Here's what investors need to know.
DN
AMEX · DNL
WisdomTree Global ex-U.S. Quality Dividend Growth Fund
Financial Services · Asset Management - Global
$46.77
Up+$0.24 (+0.52%)
Updated Aug 26, 2026, 6:15 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 480.63M
- P/E ratio
- —
- Dividend yield
- 1.79%
- 52-week range
- $38.38 – $47.46
- Volume
- 14.18K
- Avg. volume
- 68.78K
Price performance
DNL price history
1M range · 21 trading sessions · Daily adjusted prices
DNL closed at $46.77 after 21 trading sessions, up 6.03% for the selected period.
- Last close
- $46.77
- Period change
- +6.03%
- Period low
- $43.98
- Period high
- $47.24
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 25, 2026 | $46.76 | $46.80 | $46.6701 | $46.77 | 14.18K |
| Aug 24, 2026 | $46.60 | $46.60 | $46.39 | $46.528 | 10.41K |
| Aug 21, 2026 | $46.88 | $46.89 | $46.75 | $46.89 | 11.66K |
| Aug 20, 2026 | $46.45 | $46.64 | $46.4403 | $46.55 | 20.91K |
| Aug 19, 2026 | $46.87 | $46.92 | $46.625 | $46.6922 | 17.19K |
| Aug 18, 2026 | $46.57 | $46.6093 | $46.25 | $46.3364 | 14.99K |
| Aug 17, 2026 | $47.31 | $47.4183 | $47.21 | $47.2232 | 34.22K |
| Aug 14, 2026 | $47.27 | $47.27 | $46.99 | $47.0702 | 6.62K |
| Aug 13, 2026 | $47.08 | $47.33 | $47.065 | $47.239 | 11.64K |
| Aug 12, 2026 | $47.46 | $47.46 | $47.07 | $47.07 | 12.85K |
| Aug 11, 2026 | $47.18 | $47.3052 | $46.905 | $47.0183 | 45.92K |
| Aug 10, 2026 | $47.01 | $47.10 | $46.9401 | $46.9458 | 13.96K |
| Aug 7, 2026 | $46.84 | $46.905 | $46.61 | $46.799 | 15.3K |
| Aug 6, 2026 | $46.12 | $46.37 | $46.05 | $46.16 | 23.45K |
| Aug 5, 2026 | $46.50 | $46.56 | $46.24 | $46.27 | 12.7K |
| Aug 4, 2026 | $45.73 | $46.19 | $45.73 | $46.137 | 26.6K |
| Aug 3, 2026 | $45.04 | $45.35 | $44.935 | $45.22 | 15.91K |
| Jul 31, 2026 | $45.34 | $45.3451 | $44.635 | $44.96 | 23.29K |
| Jul 30, 2026 | $44.64 | $45.30 | $44.56 | $45.23 | 17.33K |
| Jul 29, 2026 | $43.95 | $44.4101 | $43.67 | $43.98 | 19.89K |
| Jul 28, 2026 | $43.87 | $44.32 | $43.86 | $44.11 | 9.25K |
Latest DNL news
The latest Smart Investors Daily articles mentioning DNL.
Stock researchCompany · Overview
DNL research
Overview
Company profile and research snapshot.
Company profile
Under normal circumstances, at least 95% of the fund's total assets (exclusive of collateral held from securities lending) will be invested in component securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities. The index is a fundamentally weighted index that consists of dividend-paying global ex-U.S. common stocks with growth characteristics. The fund is non-diversified.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
seekingalpha.com · Dec 10, 2025
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment
Denali Therapeutics Inc. is maintained at a Strong Buy rating, driven by progress in its MPS II [Hunter Syndrome] program with tividenofusp alfa. Despite discontinuing ALS efforts, DNLI's BLA for tividenofusp alfa is under FDA Priority Review under Accelerated Approval pathway, with PDUFA date extended to April 5, 2026. Company's ETV platform enables expansion into additional lysosomal storage disorders, with DNL126 for MPS IIIA offering near-term catalysts and proof of platform versatility.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
